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Genetic variants in combination with early partial
improvement as a clinical utility predictor of treatment outcome
in major depressive disorder: the result of two pooled RCTs
M Kato1, A Serretti2, S Nonen3, Y Takekita1, M Wakeno1, J Azuma3 and T Kinoshita1
Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance
prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement
by rating scales 2 weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in
patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A
stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI,
baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran,
respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (Po0.001) was significantly
associated with HAM-D change (n= 81, R2 = 0.25, Po0.001). In the fluvoxamine sample, 5-HTTLPR La/Lg, S (P= 0.029), FGF2
rs1449683C/T (P= 0.013) and EPI (P= 0.003) were associated with HAM-D change (n= 42, R2 = 0.43, Po0.001). In the milnacipran
sample, HTR-1A-1019C/G (P= 0.001), ADRA2A-1297C/G (P= 0.028) and EPI (Po0.001) were associated with outcome (n= 45,
R2 = 0.71, Po0.001). EPI in combination with genetic variants could be a useful predictor of treatment outcome and could
strengthen the practical use of pharmacogenetic data in clinical practice.
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INTRODUCTION
Major depressive disorder is a debilitating disease that causes a
significant burden not only on patients but also on society. At
present, major depressive disorder ranked third among all
diseases in the world and ranked top in 50 high-income countries
in the disability-adjusted life year in 2004 (http://apps.who.int/
gho/data/node.main.921?lang = en) despite its relatively low
mortality. The introduction and development of antidepressant
drugs has largely contributed to the treatment of major
depressive disorder, however, the evaluation of antidepressant
efficacy in the treatment of major depressive disorder usually
takes more than 4 weeks and 60% patients do not show a
significant remission after 12 weeks of treatment even with
sufficient dose of antidepressant.1,2 This leads to an increase in the
number of medications used, poor response1 and high health-care
costs.3 The failure of an initial and subsequent treatments results
in patients spending long periods of suffering. Despite results
coming from attempts to identify the best antidepressant for all
patients, it is clear from clinical practice that each patient differs in
the response to each compound.4 An accurate baseline prediction
of antidepressant response would help to evaluate the best
therapeutic tool for each patient. In this context, a large amount of
effort has been directed to the search of genetic predictors of
drug efficacy in mood disorders in the last few years and a
number of papers have reported positive associations between
genetic variants and treatment response to antidepressants. Then
in 2007 and 2010, we have reported two comprehensive meta-
analyses of antidepressant pharmacogenetic findings to
accumulate and translate findings into clinical practice.5,6 But
the variance explained by single-gene variant for antidepressant
response is low and this is in accordance with the range of effect
of single-gene variants in complex disorders7 and it means that
multiple single-nucleotide polymorphisms (SNPs) have a role in
individual difference of treatment response. Moreover, genes may
interact with the environment in determining the final
phenotype8 that in turn interacts with the drug. On the other
hand, apart from biological factors, large meta-analysis showed
that early partial improvement (EPI) defined as 20% or more
improvement by rating scale such as the Hamilton Rating Scale for
Depression (HAM-D)9 or the Montgomery–Åsberg Depression
Rating Scale10 2 weeks after treatment, is a robust predictor of
outcome with high sensitivity and negative predictive value.11 But
changing the antidepressant agent in week 2 is not common in
clinical practice. Therefore, we hypothesized that the combination
of genetic factors and EPI, having insufficient utility as predictor by
themselves, could constitute practical predictors for antidepres-
sant response that could be specific across different therapeutic
agents as well as different genetic variants.
MATERIALS AND METHODS
Subject and treatment
The analysis was performed using the clinical and genetic data retrieved
from our two open-label randomized controlled trials in patients suffering
from major depressive disorder (Figure 1).12–14 The method and design of
these two clinical trials were described elsewhere.13,14 Briefly, a total of 201
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Japanese patients consecutively admitted to the Department of Neuro-
psychiatry at Kansai Medical University Osaka, affected by major recurrent
depression, were evaluated at baseline and bi-weekly thereafter until week
6 using the 21-item HAM-D administered by trained senior psychiatrists
masked to genetic data. Patients were either drug-free or taking ineffective
antidepressants and after 10 days of washout, paroxetine (n= 51) or
fluvoxamine (n=49; trial 1) or either paroxetine (n= 50) or milnacipran
(n=51; trial 2) was randomly assigned to reach therapeutic doses from
days 8 to 11 until the end of trial (fluvoxamine: 150mg per day; paroxetine:
40mg per day, milnacipran 100mg per day). Concomitant psychotropic
drugs were not allowed, except for a low dose of sleep-inducing hypnotic
agents at bedtime. Response was evaluated by the percentage HAM-D
score change. EPI was defined as at least 20% HAM-D decrease at 2 weeks
after antidepressant medication. The study was approved by the ethics
committee of Kansai Medical University and Osaka University. Written
informed consent was obtained from all the participants before entry into
the study. Plasma levels of paroxetine, fluvoxamine and milnacipran were
determined by liquid chromatography-tandem mass spectrometry after at
least 2 weeks of stable dosage. The patients with plasma levels exceeding
the mean value of the sample+1.96 s.d. were excluded from the study to
avoid the possibility that extreme differences in the bioavailability of the
drug could influence the clinical response.
Genotyping
Candidate genetic variants were selected on the basis of our previous
meta-analyses and pharmacogenetic studies and entered into the analysis
if their contributions to antidepressant response were significant in those
studies.5,6,14–17 In detail, serotonin transporter (SLC6A4) gene promoter
polymorphism (5-HTTLPR), serotonin-2A receptor gene (HTR2A)-1438A/G
(rs6311), tryptophan hydroxylase 1 gene (TPH1) 218A/C (rs1800532) and
brain-derived neurotrophic factor (BDNF) gene 66Val/Met (rs6265) were
selected on the basis of the results of meta-analyses.5,6 Serotonin-1A
receptor gene (HTR1A)-1019C/G (rs6295),18 alpha 2A-adrenergic receptor
(ADRA2A) gene-1297C/G (rs1800544), basic fibroblast growth factor (FGF2)
gene rs1449683C/T17 and ATP-binding cassette subfamily B, membrane 1
transporter (ABCB1) gene G2677T/A (rs2032582)15 were selected on the
basis of our previous trials. In addition, functional SNP rs25532 within long
variant of 5-HTTLPR was also entered to analysis in combination with 5-
HTTLPR based on our previous study.16 Genomic DNA was isolated from
peripheral leukocytes using a QIAGEN blood Maxi kit (Qiagen, Tokyo,
Japan). Each variant was determined by TaqMan(r) SNP Genotyping Assays
or real-time polymerase chain reaction method according to a previous
study.14–17 Genotyping of our subjects was done in duplicate together with
DNA samples with known genotype as internal control and, in case of
disagreement, the analysis was repeated.
Statistical analysis
A stepwise multiple linear regression model with percent changes in
HAM-D scores at week 6 as the dependent variable and eight genetic
variants, EPI, baseline HAM-D score, age and sex as the independent
variables was performed in each antidepressant and a prediction formula
was developed. For eight genetic variants, dichotomous variables were
used based on their significant contribution observed in previous studies,
in detail, 5-HTTLPR+rs25531:LA allele carrier vs S’(LG or S) homozygotes,
HTR2A-1438A/G: G/G vs A allele carrier, TPH1 218A/C: C/C vs A allele carrier,
BDNF 66Val/Met: Met carrier vs Val homozygotes, HTR1A-1019C/G: G/G vs
C-allele carrier, ADRA2A-1297C/G: C-allele carrier vs G/G, FGF2 rs1449683C/
T: T allele carrier vs C/C and ABCB1 G2677T/A: T or A homozygotes vs G
carrier. The difference of sociodemographic and clinical characteristics
among three antidepressants were analyzed using analysis of variance or
the Chi-square test. Results were considered significant with an alpha level
o0.05. An ‘intention-to-treat’ analysis was instead carried out for the
patients who underwent a baseline and EPI (week 2) assessments; the last
observation was carried forward on the HAM-D. Statistical analyses were
carried out using IBM SPSS statistics 19 for Windows (IBM, Chicago, IL,
USA). In our sample, considering an alpha value of 0.05, we had sufficient
power (0.80) to detect, as an example for BDNF in univariate analyses, a
medium− small effect size of d= 0.46 which corresponds to a difference at
final HAM-D percent change of ~10.6 percent.19 For other variants and
multivariate analyses, the power was generally marginally lower.
RESULT
Out of 201 patients, seventeen were removed for intolerable
adverse events, four subjects for lack of compliance as displayed
by low plasma levels and thirteen patients for untraceability (that
is, lost to follow-up), therefore 168 patients were used for
subsequent analyses (Figure 1). Excluded subjects did not differ
from the analyzed sample as for sociodemographic variables (data
not shown). The genotype frequency of each SNP was the same as
NCBI data (http://www.ncbi.nlm.nih.gov/SNP/) that is: 5-HTTLPR in
combination with rs25531:LA, 26.8%, HTR2A-1438A/G: G/G 22.0%,
TPH1 218A/C: C/C 16.7%, BDNF gene 66Val/Met: Met 66.7%,
HTR1A-1019C/G: G/G 4.2%, ADRA2A-1297C/G: C 51.8%, FGF2
rs1449683C/T: T 26.2% and ABCB1 G2677T/A: T or A homozygotes
34.5%. All SNPs were in Hardy–Weinberg equilibrium.
Table 1 reports sociodemographic characteristics of the sample,
the mean HAM-D scores at baseline, HAM-D score change at week
Figure 1. Flowchart of the subjects included in the study from two
randomized controlled studies. FLV, fluvoxamine; MIL, milnacipran;
PAX, paroxetine; RCT, randomized controlled trial.
Table 1. Sociodemographic characteristics, Hamilton Rating Scale for Depression (HAM-D) baseline, HAM-D score change at week 6 and rate of early
partial improvement (EPI)
Total, N=168 PAX, N=81 FLV, N= 42 MIL, N= 45 P
Age (years) 46.3± 14.8 45.4± 15.1 45.0± 14.9 49.3± 14.3 0.297
Sex male % 53.6 55.6 52.4 51.1 0.897
HAM-D baseline 21.5± 6.1 21.7± 5.2 23.9± 7.9 19.0± 4.6 0.001
HAM-D % change 6 weeks 57.7± 32.6 63.8± 32.4 60.2± 23.9 57.7± 32.6 0.005
EPI % 58.3 65.4 57.1 46.7 0.122
Abbreviations: FLV, fluvoxamine; MIL, milnacipran; PAX, paroxetine.
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6 and rate of EPI, for all subjects and each antidepressant. No
significant differences were found for age, sex or rate of EPI, while
HAM-D score at baseline and HAM-D change at week 6 were
significantly different among three antidepressants. Lower HAM-D
baseline was observed in the milnacipran group and higher HAM-D
change was observed in the paroxetine group. In the multiple
linear regression model for the whole sample, 5-HTTLPR LA
/S’(beta=− 0.16, P= 0.013) and EPI (beta = 0.58, Po0.001) were
significantly associated with HAM-D score change at week 6
(n=168, R2 = 0.37, Po0.001). Subsequent analyses were performed
in the paroxetine, fluvoxamine and milnacipran samples to
estimate the regression equation of HAM-D score change at week
6. In the paroxetine sample, only EPI (beta= 0.50, Po0.001) was
significantly associated with HAM-D change (n=81, R2 = 0.25,
Po0.001) and the regression equation was 41.6+33.9 (EPI; yes = 1,
no= 0; Table 2). In the fluvoxamine sample, 5-HTTLPR LA/S’
(beta = 0.29, P=0.029), FGF2 RS1449683C/T (beta = 0.33, P=0.013)
and EPI (beta= 0.42, P=0.003) were significantly associated with
HAM-D change (n= 42, R2 = 0.43, Po0.001) and the regression
equation was 39.3+16.3 (5-HTTLPR; LA = 1, S’/S’=0)+16.4 (FGF2; C/
C= 0, T = 1)+19.8 (EPI; yes = 1, no= 0). In the milnacipran sample,
HTR-1A-1019C/G (beta= 0.30, P= 0.001), ADRA2A-1297C/G (beta=
0.19, P= 0.028) and EPI (beta= 0.74, Po0.001) were significantly
associated (n= 45, R2 = 0.71, Po0.001) and the regression equation
was − 28.1+52.8 (HTR1A; C = 0, G/G=1)+14.2 (ADRA2A; C = 1, G/
G=0)+54.4 (EPI; yes = 1, no= 0). For example, patients carrying 5-
HTTLPR LA, HTR1A C, ADRA2A C and FGF2 T alleles were expected
to reach at least 41.6% improvement by paroxetine, 72.0% by
fluvoxamine and −13.9% by milnacipran and when achieving more
than 20% improvement at week 2, the HAM-D improvement at
week 6 could reach 75.5, 91.8 and 40.5%, respectively. Other
polymorphisms, age and sex did not remain in the formula of
multiple linear regression analysis.
DISCUSSION
We confirmed that EPI confers a large contribution to the
treatment response at week 6 to paroxetine and milnacipran
and less to fluvoxamine and genetic variants in ADRA2A and
HTRA1A also influenced milnacipran response and 5-HTTLPR and
FGF2 influenced fluvoxamine response in the multiple linear
regression analysis.
Trajectories of treatment response to antidepressant largely
varied among the patients with major depressive disorder.20 A
great deal of effort was made to predict such an individual
treatment response from pharmacogenetic point of view with the
advancement of technology in genetic analysis. Pharmacogenetic
studies in genome-wide analyses approach might be one solution
to detect the SNP that could predict antidepressant treatment
response. However, genome-wide association studies on anti-
depressant efficacy have yielded only modest results with lack of
consistency among studies.21–23 A possible reason could be that
the variance explained by single-gene variant for antidepressant
response is low and this is in accordance with the range of effect
of single-gene variants in complex disorders. Furthermore,
different conditions of intervention, such as specific antidepres-
sants and concomitant medications could bias the efficacy of
individual genetic difference. Unfortunately, even if the robust
genetic predictor could be found in combined analysis of some
studies with different treatment setting, we could not get an
answer to the clinical question of how genetic factor can help to
select the best antidepressant for each patient in clinical practice.
Translational approach is therefore needed to help to decipher the
result of pharmacogenetic studies into real-world clinical practice.
In the present paper, we hypothesized one possible approach to
translate pharmacogenetic result into clinical use and suggested
considering genetic variants for non-EPI subjects before changing
the antidepressant agent in week 2.
Given the comparatively low R2 of one predictor, EPI, detected
in the paroxetine sample, other genetic factors may contribute to
treatment response. 5-HTTLPR LA/S’, useful predictor in the
formula of fluvoxamine, is a well-known functional polymorphism
in the transcriptional control region upstream of the serotonin
transporter coding sequence in combination with rs25531,
another functional SNP within 5-HTTLPR and the L variant with
an adenosine at SNP rs25531 (LA) has been reported to have
higher activity compared with the long variant with a guanine (LG)
1 (Hu et al.24) and LG expression is nearly equal to the s-allele. In
our previous study, LG carriers showed a reduced improvement to
fluvoxamine but not to paroxetine.16 FGF2 is a neurotrophic
molecule that is highly expressed in the adult brain and is
protective for a wide range of neurons.25 Reduced FGF2
expression was described in the brain of subjects with major
depression26,27 and the altered FGF2 expression was attenuated
by the administration of SSRIs. Rs1449683C/T of FGF2 gene is the
functional polymorphism28 and contributed to SSRI response.17 As
for prediction formula of milnacipran treatment, -1019C/G variant
in the promoter region of HTR1A was associated with an altered
expression and the function of HTR1A.29,30 G-allele is associated
with an increase of serotonin-1A autoreceptors and a reduction of
serotonergic neurotransmission31 and subjects carrying this allele
showed better treatment response to SSRI/SNRI in our previous
study18 and meta-analysis. ADRA2A is an auto receptor in the
noradrenaline system and its increased expression was observed
in the brain of suicidal patients with major depression.32 The
C-allele carrier of the ADRA2A-1297C/G polymorphism contributed
to a more favorable response than the G/G homozygote to
milnacipran, not paroxetine in our previous study.14 Other genetic
polymorphisms that have found to be associated with antide-
pressant treatment response in our previous studies and meta-
analysis such as HTR2A-1438A/G, TPH1 218A/C, BDNF 66Val/Met
and ABCB1 G2677T/A might be lacking of utility to predict
paroxetine, fluvoxamine and milnacipran treatment response in
combination with EPI may be due to small effect size compared
with EPI, that is to say that these SNPs' contribution might be
Table 2. Predictive formula of Hamilton Rating Scale for Depression (HAM-D) % change at week 6
PAX; (n= 81, R2= 0.25, Po0.001)= 41.6%+33.9%×A
FLV; (n= 42, R2= 0.43, Po0.001)= 39.3%+19.8%×A+16.3%×B +16.4%×E
MIL; (n= 45, R2= 0.71, Po0.001)=− 28.1%+54.4%×A+52.8%×C +14.2%×D
Alphabets in regression equation and frequency of favorable genotype and EPI
A; EPI Yes, (Pax, 70%; Flv, 50%; Mil, 60%)
B; 5-HTTLPR LA (26.8%), C; HTR1A-1019G/G (4.2%)
D; ADRA2A C (51.8%), E; FGF2 T (26.2%)
Abbreviations: EPI, early partial improvement; FLV, fluvoxamine; MIL, milnacipran; PAX, paroxetine. When the patient has the genotype above, corresponding
alphabet in the regression equation is 1. When the patient does not have such a genotype, corresponding alphabet in equation is 0.
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limited in real-world clinical practice to predict treatment response
of these antidepressants.
Several limitations need to be acknowledged. The relatively
small sample size lacking of genomic control is liable for
stratification bias, however, the Japanese population is considered
genetically homogeneous33 and no patient from other regions
was included in the study. A further limitation is linked to the lack
of control for possible clinical confounders such as personality
disorder, number of previous episodes, family history and previous
treatments. Candidate gene approach could not assess the SNPs
other than hypothetical genes and other genes could have
sufficient effect to treatment response that should be included to
the prediction formula. Finally, we did not test the model in an
independent sample to fully validate it.
In conclusion, we propose a practical method to apply results of
pharmacogenetic studies into clinical practice. EPI with specific
genetic variants could be a useful predictor of treatment outcome
and help personalized treatment of depression. Further prospec-
tive studies in which an antidepressant is selected or changed on
the basis of these predictive formulae will be needed to confirm
the result of this study.
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